ATE488249T1 - Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung - Google Patents
Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendungInfo
- Publication number
- ATE488249T1 ATE488249T1 AT02748276T AT02748276T ATE488249T1 AT E488249 T1 ATE488249 T1 AT E488249T1 AT 02748276 T AT02748276 T AT 02748276T AT 02748276 T AT02748276 T AT 02748276T AT E488249 T1 ATE488249 T1 AT E488249T1
- Authority
- AT
- Austria
- Prior art keywords
- hsv
- herpes simplex
- simplex virus
- amino acids
- fragment
- Prior art date
Links
- 241000700584 Simplexvirus Species 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- JSNNHGHYGYMVCK-XVKPBYJWSA-N Gly-Glu-Val Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JSNNHGHYGYMVCK-XVKPBYJWSA-N 0.000 abstract 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- GIVWETPOBCRTND-DCAQKATOSA-N Arg-Gln-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GIVWETPOBCRTND-DCAQKATOSA-N 0.000 abstract 1
- UGZUVYDKAYNCII-ULQDDVLXSA-N Arg-Phe-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UGZUVYDKAYNCII-ULQDDVLXSA-N 0.000 abstract 1
- SLQQPJBDBVPVQV-JYJNAYRXSA-N Arg-Phe-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O SLQQPJBDBVPVQV-JYJNAYRXSA-N 0.000 abstract 1
- WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 abstract 1
- 101710188313 Protein U Proteins 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30892301P | 2001-07-31 | 2001-07-31 | |
US30942801P | 2001-08-01 | 2001-08-01 | |
PCT/US2002/024306 WO2003011893A2 (en) | 2001-07-31 | 2002-07-31 | Immunologically significant herpes simplex virus antigens and methods for using same |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE488249T1 true ATE488249T1 (de) | 2010-12-15 |
Family
ID=26976523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02748276T ATE488249T1 (de) | 2001-07-31 | 2002-07-31 | Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung |
Country Status (8)
Country | Link |
---|---|
US (2) | US6814969B2 (de) |
EP (2) | EP1420821B8 (de) |
JP (1) | JP4519461B2 (de) |
AT (1) | ATE488249T1 (de) |
AU (1) | AU2002317604A1 (de) |
CA (1) | CA2454750C (de) |
DE (1) | DE60238330D1 (de) |
WO (1) | WO2003011893A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1523582T3 (da) | 2002-07-18 | 2009-03-02 | Univ Washington | Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved |
AU2004274430A1 (en) | 2003-09-12 | 2005-03-31 | Antigenics, Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
EP2460815B1 (de) | 2005-04-15 | 2015-06-03 | Human Matrix Sciences, LLC | Pflanzliche, elastinbindende Proteinliganden und deren Verwendung |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
JP5872755B2 (ja) | 2006-07-20 | 2016-03-01 | バイカル インコーポレイテッド | 抗hsv−2ワクチン接種のための組成物および方法 |
EP2185145A1 (de) | 2007-04-04 | 2010-05-19 | Board of Trustees of the University of Arkansas | Nichtspezifische verzögerte überempfindlichkeitsantwort zur behandlung von infektionen mit dem herpes simplex virus |
CN106310293A (zh) | 2007-09-27 | 2017-01-11 | 免疫疫苗技术有限公司 | 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用 |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
AU2009253780B2 (en) * | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
US8460674B2 (en) | 2009-02-07 | 2013-06-11 | University Of Washington | HSV-1 epitopes and methods for using same |
US9044447B2 (en) | 2009-04-03 | 2015-06-02 | University Of Washington | Antigenic peptide of HSV-2 and methods for using same |
MY159500A (en) * | 2009-05-22 | 2017-01-13 | Genocea Biosciences Inc | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
US20130224236A1 (en) * | 2010-11-03 | 2013-08-29 | University Of Washington | Hsv-1 epitopes and methods for using same |
WO2012074881A2 (en) | 2010-11-24 | 2012-06-07 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
EP2763698B1 (de) | 2011-10-06 | 2020-12-02 | ImmunoVaccine Technologies Inc. | Liposomzusammensetzungen mit einem adjuvans zur aktivierung oder steigerung der aktivität von tlr2 und verwendungen davon |
WO2013078299A1 (en) | 2011-11-23 | 2013-05-30 | Genocea Biosciences, Inc. | Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
RS57420B1 (sr) | 2012-05-16 | 2018-09-28 | Immune Design Corp | Vakcine za hsv-2 |
CA2976268C (en) | 2015-02-26 | 2021-07-06 | Squarex, Llc | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection |
JP2019512501A (ja) * | 2016-03-14 | 2019-05-16 | レッドバイオテック・アーゲーRedbiotec Ag | Hsvを処置するための手段及び方法 |
JP2019537555A (ja) | 2016-09-28 | 2019-12-26 | ジェノセア バイオサイエンシーズ, インコーポレイテッド | ヘルペスを処置するための方法および組成物 |
US20200164060A1 (en) * | 2017-07-21 | 2020-05-28 | Fred Hutchinson Cancer Research Center | Herpes simplex virus vaccine epitopes specifically recognized by tissue resident memory t cells |
CN112710849A (zh) * | 2020-12-24 | 2021-04-27 | 首都医科大学附属北京友谊医院 | 一种鉴定抗EBV免疫活性的ELISpot试剂盒、制备方法及应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859587A (en) | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
EP0541692B1 (de) | 1990-08-02 | 1999-05-06 | Chiron Corporation | Herpes simplex virus vp16 impfstoffe |
CA2090295A1 (en) | 1992-02-03 | 1993-08-04 | Anthony B. Nesburn | Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
JPH11510386A (ja) | 1995-07-28 | 1999-09-14 | マリー キュリー キャンサー ケア | 輸送蛋白質およびそれらの使用 |
GB9615726D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Anti-viral agent 11 |
EP0948508A4 (de) | 1996-11-04 | 2001-11-07 | Smithkline Beecham Corp | Kodierungssequenzen vom herpes-simplex-virus typ 2 |
US6017735A (en) * | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
EP0984790A1 (de) * | 1997-06-02 | 2000-03-15 | Chiron Corporation | Impfstoff gegen herpes simplex viren enthaltend vp22 und dessen verwendungen |
KR20010085348A (ko) * | 1998-08-07 | 2001-09-07 | 추후보정 | 면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법 |
JP2003512305A (ja) * | 1999-09-30 | 2003-04-02 | ユニバーシティ オブ ワシントン | 免疫学的に重要な単純疱疹ウイルス抗原 |
US6821519B2 (en) * | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
JP2004501663A (ja) * | 2000-06-29 | 2004-01-22 | コリクサ コーポレイション | 単純疱疹ウイルス感染の診断および処置のための組成物および方法 |
-
2002
- 2002-07-31 AT AT02748276T patent/ATE488249T1/de not_active IP Right Cessation
- 2002-07-31 AU AU2002317604A patent/AU2002317604A1/en not_active Abandoned
- 2002-07-31 CA CA2454750A patent/CA2454750C/en not_active Expired - Fee Related
- 2002-07-31 EP EP02748276A patent/EP1420821B8/de not_active Expired - Lifetime
- 2002-07-31 DE DE60238330T patent/DE60238330D1/de not_active Expired - Lifetime
- 2002-07-31 WO PCT/US2002/024306 patent/WO2003011893A2/en active Application Filing
- 2002-07-31 US US10/210,428 patent/US6814969B2/en not_active Expired - Fee Related
- 2002-07-31 EP EP10151241A patent/EP2191845A1/de not_active Withdrawn
- 2002-07-31 JP JP2003517084A patent/JP4519461B2/ja not_active Expired - Fee Related
-
2004
- 2004-06-30 US US10/882,074 patent/US7037509B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2002317604A1 (en) | 2003-02-17 |
US20040241182A1 (en) | 2004-12-02 |
EP1420821B8 (de) | 2011-02-02 |
WO2003011893A2 (en) | 2003-02-13 |
EP1420821A2 (de) | 2004-05-26 |
DE60238330D1 (de) | 2010-12-30 |
EP1420821B1 (de) | 2010-11-17 |
JP4519461B2 (ja) | 2010-08-04 |
WO2003011893A3 (en) | 2003-09-12 |
EP2191845A1 (de) | 2010-06-02 |
JP2004537308A (ja) | 2004-12-16 |
US7037509B2 (en) | 2006-05-02 |
US20030190324A1 (en) | 2003-10-09 |
US6814969B2 (en) | 2004-11-09 |
CA2454750C (en) | 2012-09-18 |
CA2454750A1 (en) | 2003-02-13 |
EP1420821A4 (de) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE488249T1 (de) | Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung | |
MX9702714A (es) | Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral. | |
EP2011510A3 (de) | Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten | |
BG102983A (en) | Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application | |
ECSP064643A (es) | Proteinas de fusion de glp-1 | |
CA2111645A1 (en) | Fibrinogen fragment e peptides and antibodies thereto | |
IL135687A0 (en) | A novel human checkpoint kinase, hcds1, compositions and methods | |
ATE298798T1 (de) | Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin | |
DE69233311D1 (de) | Weidelgraspollen-allergen | |
FI930626A (fi) | Proteinstruktur hos vaexttoxingelonin | |
DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
ES2110996T3 (es) | Alergeno de polen de ballico. | |
AU1444699A (en) | Single-chain polypeptides comprising troponin i and troponin | |
ATE108802T1 (de) | Polypeptidhemmer für virale replikation. | |
DE69928947D1 (de) | Moraxella catarrhalis basb034 polypeptide und verwendungen davon | |
EA200100314A1 (ru) | Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины | |
ATE234358T1 (de) | Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test | |
AU6393990A (en) | Hiv related peptides | |
DE69827880D1 (de) | Iga1-protease fragment als trägerpeptid | |
WO2001070774B1 (en) | Human t cell response to mhc-binding motif clusters | |
NZ606260A (en) | Novel polypeptides involved in immune response | |
MY106940A (en) | Allelic variants of plasmodium falciparum merozoite surface antigen. | |
WO2002000832A3 (fr) | Nouveau polypeptide, proteine p80-coiline 8.8, et polynucleotide codant ce polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |